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doi:10.1016/j.jfma.2012.03.007Epileptic encephalopathy with suppression-burst in electroencephalography (EEG) can evolve
into a few types of epileptic syndromes. We present here an unusual case of early myoclonic
encephalopathy that evolved into migrating partial seizures in infancy. A female neonate
initially had erratic myoclonus movements, hiccups, and a suppression-burst pattern in EEG
that was compatible with early myoclonic encephalopathy. The seizures were controlled with
dextromethorphan (20 mg/kg), and a suppression-burst pattern in EEG was reverted to rela-
tively normal background activity. However, at 72 days of age, alternating focal tonic seizures,
compatible with migrating partial seizures in infancy, were demonstrated by the 24-hour EEG
recording. The seizures responded poorly to dextromethorphan. To our knowledge, this is the
first reported case of early myoclonic encephalopathy evolving into migrating partial seizure in
infancy. Whether it represents another age-dependent epilepsy evolution needs more clinical
observation.
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Early infantile epileptic encephalopathy (EIEE) with
suppression-bursts (Ohtahara syndrome) and early myo-
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and intractable seizures in clinical presentations. EIEE is
usually associated with brain structural anomaly, while EME
is frequently associated with an inborn error of metabo-
lism.1 Nonketotic hyperglycinemia is one of the major
causes of EME and the response to dextromethorphan (DM)
treatment is good.1,2 DM, a morphine derivative, is
a commonly used antitussive drug, and it is also a noncom-
petitive N-methyl-D-aspartate (NMDA) receptor antagonist
and voltage-dependent calcium and sodium channel
blocker.3 Although the use of DM is well established in
patients with nonketotic hyperglycinemia, the use of DM in
other types of epilepsy is not well known.4e7
Epileptic encephalopathy with suppression-burst pattern
in EEG frequently evolves into other epileptic syndromes.
Of these, EIEE can evolve into West syndrome, severe
epilepsy with multiple independent spike foci, Lennox-
Gastaut syndrome, and symptomatic partial epilepsy.1
However, the evolution of EME is less documented. We
report one patient with EME that was diagnosed at 40 days
of age. The seizures were totally controlled by DM, and the
suppression-burst pattern in EEG was changed to a nearly
normal background activity. However, she developed
alternating asymmetric tonic seizure 34 days later with
characteristics of migrating partial seizure in infancy (MPSI)
in both the clinical and EEG features. The response to DMFigure 1 (A) Initial EEG evaluation showing the suppression-burs
suppression-burst pattern with a nearly normalization of the backg
methorphan. EEG Z electroencephalography.was also poor at that time. The seizures were changed to
infantile spasms 3 months later with the appearance of
hypsarrhythmia in EEG.Case report
A female baby was born smoothly by cesarean section to
a G3P2SA1 mother aged 36 years; the baby had a gesta-
tional age of 36 weeks and a birth body weight of
1774 g.The head girth at birth was 30 cm (<third percen-
tile). Myoclonus-like movements with hiccups were noted
by the mother while the baby was awake and asleep ever
since the patient was 20 days of age. The baby girl was then
admitted for evaluation. On physical examination, there
was no microcephaly, craniofacial dysmorphism, hep-
atosplenomegaly, and any other abnormality. The head
circumference was 33.8 cm (third percentile). On neuro-
logic examination, she had mild hypotonia, normoreflexia,
and normal primitive reflexes, including positive grasping
reflex, sucking, rooting reflexes, and Moro reflex. She also
had normal cranial nerve examination with bilateral posi-
tive light reflex, gag reflex, and symmetric crying face, but
she had poor eye contact. There was no optic atrophy or
retinitis pigmentosa found during a fundus examination.
During the admission period, metabolic evaluationst pattern at 40 days of age; and (B) the disappearance of the
round activity at 52 days of age after treatment with dextro-
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normal blood gas, and urine sulfite. Plasma and cerebro-
spinal fluid tandem mass, urine organic acid study, plasma
amino acids were unrevealing. Levels of very long chain
fatty acid were normal. Cerebrospinal fluid examinations
revealed a normal cell count and normal levels of neuro-
transmitters, 5-methyltetrahydrofolate, and glycine. Brain
magnetic resonance imaging and spectroscope revealed
negative findings. Brain auditory evoked potential was
within the normal limit. The seizure characteristics were
frequent, erratic, and massive myoclonus with hiccups,
desaturation, and bradycardia, all of which were compat-
ible with EME. The EEG revealed suppression-burst pattern
in sleeping (Fig. 1A). Initial treatments, including
phenytoin, phenobarbital, midazolam, and high dose pyri-
doxine, failed to control the seizures. DM (20 mg/kg/day)
was then applied at 44 days of age for suspected nonketotic
hyperglycinemia. The myoclonus greatly improved after
treatment, and only occasional hiccups and bradycardia
were found at 47 days of age. The follow-up EEG at 52 days
of age revealed a nearly normal background activity with
occasional focal spikes over the left frontocentral area
(Fig. 1B). DM was tapered off due to normal cerebrospinal
fluid glycine level at 61 days of age. However, the new
seizure type developed 1 week later, and it was charac-
terized with alternating asymmetric tonic seizures. A
24-hour video EEG revealed ictal attacks arising from the
right-central temporooccipital areas that spread into the
left hemisphere, followed by another attack arising from
the left frontocentral and temporo-occipital areas (Fig. 2).
The interictal EEG revealed multiple focal spikes in the
bilateral central, temporal, and occipital areas, all of
which were compatible with MPSI. Although multiple anti-
epileptic drugs were used, she still suffered from frequent
asymmetric tonic seizures. DM was added again, but it still
failed to control the seizures. After 3 months, the infant
developed tonic spasms. EEG revealed hypsarrhythmia
pattern, which was compatible with infantile spasms
(Fig. 3). The seizures were resistant to different kinds of
antiepileptic drugs, and she still has occasional tonic
spasms at 2 years of age.Discussion
Epileptic encephalopathy with suppression-bursts is divided
into two syndromes, EIEE and EME. Patients with EIEE are
frequently associated with different brain malformations,1
and the condition has a consistent evolution into other
epileptic syndromes. By contrast, patients with EME are
occasionally associated with genetic factors or inborn
errors of metabolism, such as nonketotic hyperglycinemia.8
However, the underlying cause is usually not found in most
patients with EME. EME occurs mainly in the neonatal
period, with erratic myoclonus movement at first that may
become tonic spasms later on. The suppression-burst in EEG
is noted only during the sleep period. Although EME
candbut rarelydevolve into West syndrome, severe
epilepsy with multiple independent spike foci, and symp-
tomatic partial epilepsy, most patients with EME do not
have a consistent evolution.1 There was no previous report
of EME evolving into MPSI, which was a newly epilepsysyndrome addressed in the International League Against
Epilepsy’s commission report in 2001.9 Ohtahara syndrome
and EME share common clinical and EEG characteristics,
such as onset in the first few months of life and a suppres-
sion-burst pattern on EEG, but there are several features
that distinguish these two disorders.8e10 These two
syndromes can be differentiated mainly in the seizure
types, underlying conditions, ictal EEG, and the seizure
transition. However, occasional cases are truly difficult to
separate because of the underlying cerebral malformation
and metabolic/genetic disorders.8,11e13 In our patient, she
did not have a brain anomaly, and the seizure type was
mainly erratic myoclonia. Therefore, EME is the diagnosis of
this patient.
MPSI was first reported by Coppola in 1995,14 and it is
characterized by: (1) normal development before seizure
onset, (2) seizure onset before 6 months without identified
etiology, (3) migrating focal motor seizures at onset, nearly
continuous, and becoming intractable, (4) intractability to
conventional antiepileptic drugs and corticosteroids, and
(5) profound psychomotor developmental delay. Some
studies show a better prognosis with a better seizure
control in patients without continuous seizures.15 The ictal
EEG shows focal rhythmic theta activity shifting from one
hemisphere to the other and progressively involving adja-
cent areas like what was seen in the present case. Except
for the presence of abnormal development, our patient had
typical clinical and EEG features of MPSI, and she fulfilled
the diagnostic criteria.16 Whether EME that evolves into
MPSI represents one special type of age-dependent epilepsy
evolution is a question that requires more clinical obser-
vations to answer.
The therapy for MPSI has not yet been established.
Conventional antiepileptics did not show any effect on MPSI
by definition. Two patients reported by Okuda and
colleagues 17 who were refractory to conventional antiep-
ileptic drugs were eventually controlled with potassium
bromide. Another two patients treated with combined
clonazepam and stiripentol had some response.17 New
epileptic drugs such as zonisamide and topiramate were
found to be ineffective, and, in one case, levetiracetam
decreased seizure frequency and improved both the clinical
picture and EEG recording.18
Although widely used in patients with nonketotic
hyperglycinemia, the experience of DM usage in children
with epilepsy is limited.2e7 DM is effective in elevating the
threshold for the cough reflex, suppressing convulsions or
their experimental correlate, and reducing the neuronal
damage induced by ischemia or excitatory amino acids.4
DM is demethylated to the D-isomer of levorphanol, dex-
trorphan (DX) in vivo. It is believed that the anticonvulsant
effect of DM is due to NMDA-R inhibition, and DX is the
predominant inhibitor of the NMDA-R in vivo. In recent
studies, high dose of DM offered neuroprotection and
improved neurologic recovery, and they also have effects
in seizure reduction in both children and adults with
epilepsy.3,4 Very low doses (6e20 mg/day) of DM as an
add-on therapy have also been shown to induce a signifi-
cant reduction in seizure frequency and severity.5
However, a low-dose (2 mg/kg/day) double-blinded,
crossover, add-on study in nine patients with complex
partial seizures showed no beneficial effects.6 A study
Figure 2 One episode of asymmetric tonic seizure in a 24-hour video EEG recording at 72 days of age showed focal spikes arising
from the right-central temporooccipital area with spreading to the left hemisphere, which was followed by a relative flattening of
right hemisphere. The clinical feature showed a left-side asymmetric tonic seizure. It was followed by a right-side tonic seizure,
which is when the EEG revealed focal spikes over left the frontocentral and temporo-occipital areas. The presentation
is compatible with migrating partial seizures in infancy. The arrows indicate the clinical onset of seizures.
EEG Z electroencephalography.
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had no effect on the nonconvulsive seizure in animal
models of focal brain ischemia.19 DM suppressed audio-
genic seizure manifestation effectively in primed rats.20
This effect of DM was consistent with its anticonvulsive
effects, and the effective doses were below those repor-
ted in other models.21,22 Although high dose DM (5e35 mg/
kg/day) is routinely used with sodium benzoate in the
treatment of nonketotic hyperglycinemia, rapid escalation
of both hypertonia and seizures were found after dis-
continued DM use ,7 indicating a significant role of DM inseizure reduction. Although the present case of EME was
not secondary to nonketotic hyperglycinemia, DM was also
effective in the control of seizures, leading to the disap-
pearance of a suppression-burst pattern in EEG. However,
DM was not effective for the control of migrating partial
seizures in the present case.
In conclusion, we present a case of MPSI evolved from
EME. The migrating partial seizures finally evolved into
infantile spasms during the follow-up period. Although the
patient did not have nonketotic hyperglycinemia, the
erratic myoclonus responded very well to DM treatment.
Figure 3 Follow-up EEG 3 months later revealed a hypsarrhythmia pattern compatible with infantile spasms.
EEG Z electroencephalography.
294 Y.-H. Chien et al.However, DM is not effective for the control of migrating
partial seizures in the present case. The role of DM usage in
neonatal seizure or status epilepticus even in those without
nonketotic hyperglycinemia should, therefore, be reeval-
uated in the future.
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